Acorda Therapeutics, Inc.

Company Information

Company Name
Acorda Therapeutics, Inc.
Address
15 Skyline Drive
Hawthorne, NY, 10532
Phone
1 914-347-4300
URL
n/a
DUNS
n/a
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,040,363.00
8
STTR Phase I
$295,521.00
3
STTR Phase II
$980,125.00
1

Award List

  1. N/A

    Amount: $100,000.00

    Not Available If the development of a vehicle capable of sustained hypersonic flight in the atmosphere at speeds above Mach 8 is to be realized, a ground-based wind tunnel with a reliable force measu ...

    SBIR Phase I 2000 Department of Health and Human Services
  2. N/A

    Amount: $195,526.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services
  3. PROMOTION OF NERVE REGENERATION BY FRAGMENTS OF L1

    Amount: $99,995.00

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  4. Antisense Technology for Neural Protection and Repair

    Amount: $139,371.00

    Spinal Cord Injury (SCI) is a devastating condition for which there is no effective treatment. The cost to society is enormous because most new cases occur in people under the age of 30 and these indi ...

    SBIR Phase I 2001 Department of Health and Human Services
  5. Tenascin-C-Fragments for Spinal Cord Regeneration

    Amount: $100,000.00

    The goal of this project is to conduct pre-clinical tests of components of the extracellular matrix molecule tenascin-C that offer potential as therapeutics for enhancing nerve fiber re ...

    SBIR Phase I 2001 Department of Health and Human Services
  6. HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION

    Amount: $0.00

    DESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimula ...

    STTR Phase I 2002 Department of Health and Human Services
  7. HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION

    Amount: $980,125.00

    DESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimula ...

    STTR Phase II 2002 Department of Health and Human Services
  8. Release Chondroitinase Systems for Spinal Cord Injury

    Amount: $107,300.00

    DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and causes a severe and debilitating condition in the individual. F ...

    SBIR Phase I 2003 Department of Health and Human Services
  9. Molecular Evolution of Chondroitinase ABCI for SCI

    Amount: $184,388.00

    DESCRIPTION (provided by applicant): Spinal cord injury (SCI) is a devastating event affecting approximately 11,000 individuals each year in the US alone. Although most victims survive, the individua ...

    SBIR Phase I 2005 Department of Health and Human Services
  10. Effects of Chondroitinase and Training in Acute SCI

    Amount: $156,491.00

    DESCRIPTION (provided by applicant): Spinal cord injury (SCI) inflicts trauma to the cells and tissues of the central nervous system and typically results in debilitating loss of function below the le ...

    SBIR Phase I 2005 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government